>> IT IS TIME FOR THE LIGHTNING ROUND. BUY BUY. >> BUY SELL SUZANNE BRENNER.MR. PRESIDENT, YOU SOUND. AND THEN THE LIGHTNING ROUND IS OVER.ARE YOU READY, SKI DADDY. TIME FOR THE LIGHTNING ROUND. LET'S GO TO SAM IN PENNSYLVANIA.SAM. >> JIM, HOW ARE YOU. >> ALL RIGHT.HOW ARE YOU DOING. >> GOOD. YOU KNOW, JIM, LAST WEEK WE HAD A BIG ACQUISITION OF A CYBERSECURITY COMPANY BY SERVICENOW TALKING ABOUT ARMIS FOR 7 BILLION.SO IT CAUGHT MY ATTENTION BECAUSE SENTINEL ONE HAS BEEN LONG ON MY RADAR. SO I'M CURIOUS WHAT ...

The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE:MRK) drugs with potential blockbuster sales.Merck's cholesterol treatment enlicitide decanoate and cancer therapy sacituzumab tirumotecan (sac-TMT) have been reportedly selected for the FDA Commissioner's National Priority Voucher (CNPV) program, which accelerates regulatory decisions for medicines deemed critical to public health or national interests.If finalized, the drugs would becom ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters. ...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s ahead for MRK stock?The trial showed Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically significant and clinically meani ...

Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month after the company laid out a cautious 2026 outlook, acknowledging that the post-COVID reset isn't over yet. Track PFE stock here.Management flagged flat-to-low single-digit growth expectations, with COVID product declines continuing to fade out of the base. The market's response was telling: shares slipped, but ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV- 304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signific. ...

Key Takeaways MRK gets positive CHMP opinion for expanded Winrevair use in adult PAH patients with WHO FC II, III and IV.The recommendation is based on phase III ZENITH data showing a 76% reduction in morbidity and mortality risk.The opinion will be reviewed by the European Commission, with a final decision expected in Q1 2026.Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending approval of an expanded ...

Core Insights - BioVaxys Technology Corp. has appointed Dr. Marianne Stanford as Scientific Advisor, bringing extensive experience in vaccine development and immunotherapy [1][4] - Dr. Stanford previously led the R&D at IMV Inc., where she developed the DPX™ vaccine portfolio, demonstrating enhanced efficacy in cancer models through innovative combinations [1][2] - The company focuses on novel immunotherapies using the DPX platform, targeting cancers and infectious diseases, with ongoing clinical trials for multiple products [4] Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada, dedicated to developing immunotherapies for various diseases [4] - The DPX platform is designed to generate specific and robust immune responses, with a clinical pipeline that includes MVP-S for advanced cancers and other immunotherapies [4] Dr. Stanford's Background - Dr. Stanford holds a PhD in Microbiology and Immunology and has a strong background in viral immunotherapy and oncology, enhancing her role at BioVaxys [3] - Her previous role as Chief Scientific Officer at Mara Renewables Corp. involved the commercialization of bio-based nutrition products, showcasing her leadership in scientific research [2]

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficiency for the Company. “Mohamad brings a wealth of experience in strategic planning and business development,” said Vish Seshadri, Chief Executive Officer of Abeona. “W ...